74
Participants
Start Date
November 30, 2005
Primary Completion Date
May 31, 2008
Study Completion Date
October 31, 2009
MDX-060
anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
Mount Sinai School of Medicine, New York
Roswell Park Cancer Center, Buffalo
Carolina BioOncology Institute, PLLC, Huntersville
H. Lee Moffitt Cancer & Research Institute, Tampa
St. Francis Hospital Center, Beech Grove
American Health Network of Indiana, Indianapolis
Henry Ford Health System, Detroit
Mayo Clinic, Rochester
Rush Cancer Institute, Chicago
M.D. Anderson Cancer Center, The University of Texas, Houston
Nevada Cancer Institute, Las Vegas
City of Hope, National Medical Center, Duarte
California Oncology of the Central Valley, Fresno
University of California, San Diego/Moores UCSD Cancer Center, La Jolla
Division of Hematology/Oncology, Tufts-New England Medical Center, Boston
The Cancer Institute of New Jersey, New Brunswick
Mary Babb Randolph Cancer Center, Morgantown
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY